Clinical Trial Update: Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating JX-594 for peritoneal carcinomatosis of ovarian cancer origin has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• JX-594

Snippet

Sponsor: Andrea McCart | Conditions: Ovarian Cancer | Phase 2 | Status: WITHDRAWN